Real-time endpoint monitoring and determination for a pharmaceutical salt formation process with in-line FT-IR spectroscopy

Journal of Pharmaceutical and Biomedical Analysis

Volumn 41, Issue 1, 2006, Pages 99-104

  Lin, Zhihao ^a   Zhou, Lili ^a   Mahajan, Amar ^a   Song, Sherry ^a   Wang, Tao ^a   Ge, Zhihong ^a   Ellison, Dean ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

ATR FT IR; In line FT IR; Principal component analysis; Process analytics technology; Reaction endpoint determination; Salt formation of pharmaceutical compound

Indexed keywords

4 [1 METHYL 2 PIPERIDIN 4 YL 4 [3 (TRIFLUOROMETHYL)PHENYL] 1H IMIDAZOL 5 YL] N [1 PHENYLETHYL]PYRIDINE 2 AMINE; MITOGEN ACTIVATED PROTEIN KINASE P38 INHIBITOR; PYRIDINE DERIVATIVE; SODIUM CHLORIDE; UNCLASSIFIED DRUG;

ARTICLE; CHEMICAL REACTION KINETICS; DRUG PURITY; DRUG STRUCTURE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; INFRARED SPECTROSCOPY; ONLINE MONITORING; PRINCIPAL COMPONENT ANALYSIS; PRIORITY JOURNAL; QUALITATIVE ANALYSIS; REFLECTOMETRY; TITRIMETRY;

CALIBRATION; CHEMISTRY, PHARMACEUTICAL; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; MODELS, CHEMICAL; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PHARMACEUTICAL PREPARATIONS; PRINCIPAL COMPONENT ANALYSIS; SALTS; SPECTROSCOPY, FOURIER TRANSFORM INFRARED; TECHNOLOGY, PHARMACEUTICAL;

EID: 33645060732     PISSN: 07317085     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jpba.2005.10.028     Document Type: Article

References (17)

1. P.H. Stahl, and C.G. Wermuth Handbook of Pharmaceutical Salt Properties, Selection and use 2002 Wiley-VCH Weinheim, NY
2. J.A. Murry Curr. Opin. Drug Discov. 6 2003 945 965
3. W.Q. Gong Int. J. Miner. Process. 63 2001 147 165
4. M Palucki, Z.H. Lin, and Y. Sun Org. Process Res. Dev. 9 2005 141 148
5. D.J. Watson, E.D. Dowdy, J.S. DePue, A.S. Kotnis, S. Leung, and B.C. O'-Reilly Org. Process Res. Dev. 8 2004 616 623
6. R.N. Landau, P.F. McKenzie, A.L. Forman, R.R. Dauer, M. Futran, and A.D. Epstein Process Control Qual. 7 1995 133 142
7. Y.D. Chen, T. Wang, R. Helmy, G.X. Zhou, and R. LoBrutto J. Pharm. Biomed. Anal. 29 2002 393 404
8. C. LeBlond, J. Wang, R. Larsen, C. Orella, and Y.K. Sun Top. Catal. 5 1998 149 158
9. A. Horvath, K. De Smet, D. Ormerod, D. Depre, C. Perez-Balado, T. Govaerts, D. Van-den-Heuvel, and I. Schorpion Org. Process Res. Dev. 9 2005 356 359
10. K. Kargosha, M. Khanmohammadi, M. Sarokhani, F. Ansari, and M. Ghadiri J. Pharm. Biomed. Anal. 31 2003 571 577
11. G. Fevotte Int. J. Pharm. 241 2002 263 278
12. N. Doki, H. Seki, K. Takano, H. Asatani, M. Yokota, and N. Kubota Crystal Growth Des. 4 2004 949 953
13. V. Liotta, and V. Sabesan Org. Process Res. Dev. 8 2004 488 494
14. K. Pollanen, A. Hakkinen, S.P. Reinikainen, J. Rantanen, M. Karjalainen, M. Louhi-Kultanen, and L. Nystrom J. Pharm. Biomed. Anal. 38 2005 275 284
15. S. Wold, M. Sjostrom, Society Symp, Ser. No. 52, American Chemical Society, Washington, DC, 1977, pp. 243-282.
16. J.H. Chen, and K.C. Liu Chem. Eng. Sci. 57 2002 63 75
17. X. Wang, U. Kruger, and G.W. Irwin Ind. Eng. Chem. Res. 44 2005 5691 5702